Our findings provide novel insights into the understanding of inflammatory bowel disease and suggest that targeting TGF‐β signaling activity in individuals with TSP50 deficiency may contribute to enhancing mucous protection and preventing/alleviating colitis. The gene discussed is TGFB1; the disease is colitis.